

Sooryanarayana Varambally

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3485645/publications.pdf>

Version: 2024-02-01

143
papers

35,692
citations

13827

67
h-index

9553

142
g-index

156
all docs

156
docs citations

156
times ranked

36920
citing authors

#	ARTICLE	IF	CITATIONS
1	Global molecular alterations involving recurrence or progression of pediatric brain tumors. <i>Neoplasia</i> , 2022, 24, 22-33.	2.3	7
2	MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common \hat{I}^2 -chain cytokine receptor endocytosis. <i>Blood</i> , 2022, 139, 761-778.	0.6	7
3	UALCAN: An update to the integrated cancer data analysis platform. <i>Neoplasia</i> , 2022, 25, 18-27.	2.3	666
4	DCZ0415, a small molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/ \hat{I}^2 catenin pathway in colorectal cancer. <i>Molecular Oncology</i> , 2022, 16, 1728-1745.	2.1	13
5	Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemic. <i>BMJ Open</i> , 2022, 12, e053912.	0.8	1
6	Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways. <i>Nature Communications</i> , 2022, 13, 2669.	5.8	78
7	Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers. <i>Cancers</i> , 2022, 14, 2447.	1.7	6
8	Reducing regorafenib toxicity by combining with dual JAK-HDAC inhibitor in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15597-e15597.	0.8	0
9	Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes. <i>Breast Cancer</i> , 2021, 28, 496-505.	1.3	7
10	Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers. <i>Oncogene</i> , 2021, 40, 2081-2095.	2.6	22
11	<i><i>NAB2-STAT6</i></i> Gene Fusions to Evaluate Primary/Metastasis of Hemangiopericytoma/Solitary Fibrous Tumors. <i>American Journal of Clinical Pathology</i> , 2021, 156, 906-912.	0.4	3
12	Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women. <i>Translational Oncology</i> , 2021, 14, 101086.	1.7	17
13	Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma. <i>Translational Oncology</i> , 2021, 14, 101128.	1.7	10
14	Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells. <i>Scientific Reports</i> , 2021, 11, 16212.	1.6	15
15	The TGF- \hat{I}^2 /HDAC7 axis suppresses TCA cycle metabolism in renal cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	9
16	Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancer. <i>Frontiers in Bioscience</i> , 2021, 26, 765.	0.8	7
17	MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common \hat{I}^2 Chain Cytokine Receptor Endocytosis. <i>Blood</i> , 2021, 138, 59-59.	0.6	0
18	14-3-3 proteins protect AMPK-phosphorylated ten-eleven translocation-2 (TET2) from PP2A-mediated dephosphorylation. <i>Journal of Biological Chemistry</i> , 2020, 295, 1754-1766.	1.6	21

#	ARTICLE	IF	CITATIONS
19	Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. <i>Cancer Letters</i> , 2020, 470, 134-140.	3.2	53
20	TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. <i>Molecular Oncology</i> , 2020, 14, 3007-3029.	2.1	24
21	PGC1 α suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression. <i>Matrix Biology</i> , 2020, 89, 43-58.	1.5	17
22	PRDM16 suppresses HIF-targeted gene expression in kidney cancer. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	33
23	EZH2-Targeted Therapies in Cancer: Hype or a Reality. <i>Cancer Research</i> , 2020, 80, 5449-5458.	0.4	139
24	PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. <i>Translational Oncology</i> , 2020, 13, 100776.	1.7	19
25	Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer. <i>PLoS ONE</i> , 2020, 15, e0234726.	1.1	4
26	Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model. <i>Translational Oncology</i> , 2020, 13, 100754.	1.7	28
27	Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G955-G965.	1.6	3
28	PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer. <i>Cancers</i> , 2020, 12, 772.	1.7	32
29	MicroRNA-mediated inflammation and coagulation effects in rats exposed to an inhaled analog of sulfur mustard. <i>Annals of the New York Academy of Sciences</i> , 2020, 1479, 148-158.	1.8	10
30	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. <i>Oncogene</i> , 2020, 39, 4077-4091.	2.6	19
31	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. <i>Molecular Cancer Research</i> , 2019, 17, 84-96.	1.5	37
32	Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. <i>Laboratory Investigation</i> , 2019, 99, 371-386.	1.7	77
33	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. <i>Translational Oncology</i> , 2019, 12, 1416-1424.	1.7	21
34	Characterization of glycine N-acyltransferase like 1 (GLYATL1) in prostate cancer. <i>Prostate</i> , 2019, 79, 1629-1639.	1.2	12
35	MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal Cancer. <i>Translational Oncology</i> , 2019, 12, 1461-1467.	1.7	42
36	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 989-1002.	2.3	15

#	ARTICLE	IF	CITATIONS
37	Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer. <i>Oncolmunology</i> , 2019, 8, 1548241.	2.1	76
38	The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype. <i>PLoS ONE</i> , 2019, 14, e0211734.	1.1	7
39	Ferritin Light Chain Confers Protection Against Sepsis-Induced Inflammation and Organ Injury. <i>Frontiers in Immunology</i> , 2019, 10, 131.	2.2	64
40	Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. <i>Nature Communications</i> , 2019, 10, 5679.	5.8	358
41	Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. <i>Cancer</i> , 2019, 125, 921-932.	2.0	42
42	Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas. <i>Molecular Cancer Research</i> , 2019, 17, 476-487.	1.5	28
43	Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 591-602.	1.9	71
44	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. <i>European Urology Focus</i> , 2018, 4, 733-736.	1.6	18
45	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2018, 16, 1125-1137.	1.5	51
46	Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. <i>Matrix Biology</i> , 2018, 65, 104-118.	1.5	172
47	Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. <i>Prostate</i> , 2018, 78, 1311-1320.	1.2	25
48	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. <i>Neoplasia</i> , 2018, 20, 894-904.	2.3	50
49	Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 179-184.	0.6	6
50	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. <i>Scientific Reports</i> , 2017, 7, 43984.	1.6	20
51	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell</i> , 2017, 31, 532-548.e7.	7.7	85
52	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 253-271.	0.1	2
53	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. <i>Neoplasia</i> , 2017, 19, 649-658.	2.3	4,166
54	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. <i>Prostate</i> , 2017, 77, 10-21.	1.2	37

#	ARTICLE	IF	CITATIONS
55	Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance. <i>Frontiers in Oncology</i> , 2017, 7, 256.	1.3	16
56	MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. <i>Oncogene</i> , 2016, 35, 6330-6340.	2.6	74
57	Genomic and Epigenomic Alterations in Cancer. <i>American Journal of Pathology</i> , 2016, 186, 1724-1735.	1.9	130
58	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , 2016, 22, 298-305.	15.2	1,193
59	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. <i>Nature Immunology</i> , 2016, 17, 95-103.	7.0	310
60	EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation. <i>Blood</i> , 2016, 128, 5301-5301.	0.6	0
61	Increased Expression of EZH2 Is Associated with Inferior Survival in Primary Central Nervous System Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 4216-4216.	0.6	0
62	Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. , 2016, 2016, .		0
63	Role and regulation of coordinately expressed <i>de novo</i> purine biosynthetic enzymes <i>PPAT</i> and <i>PAICS</i> in lung cancer. <i>Oncotarget</i> , 2015, 6, 23445-23461.	0.8	80
64	The kinase activity of the Ser/Thr kinase BUB1 promotes TGF- β 2 signaling. <i>Science Signaling</i> , 2015, 8, ra1.	1.6	72
65	Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. <i>Cell Cycle</i> , 2015, 14, 2798-2809.	1.3	22
66	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. <i>Nature Communications</i> , 2014, 5, 4527.	5.8	129
67	The miR-124-Prolyl Hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. <i>Oncotarget</i> , 2014, 5, 6654-6669.	0.8	82
68	Prostate Cancer Genomics: Progress and Promise. <i>European Urology</i> , 2013, 64, 577-578.	0.9	1
69	Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer. <i>Molecular Cell</i> , 2013, 49, 80-93.	4.5	130
70	Targeting the link between late pregnancy and breast cancer. <i>ELife</i> , 2013, 2, e01926.	2.8	4
71	The Enzymatic Activity of Apoptosis-inducing Factor Supports Energy Metabolism Benefiting the Growth and Invasiveness of Advanced Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 43862-43875.	1.6	19
72	Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. <i>Blood</i> , 2012, 119, 1274-1282.	0.6	70

#	ARTICLE	IF	CITATIONS
73	Role of Transcriptional Corepressor CtBP1 in Prostate Cancer Progression. <i>Neoplasia</i> , 2012, 14, 905-IN8.	2.3	59
74	Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. <i>Prostate</i> , 2012, 72, 1542-1549.	1.2	13
75	Therapeutic Targeting of SPINK1-Positive Prostate Cancer. <i>Science Translational Medicine</i> , 2011, 3, 72ra17.	5.8	140
76	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. <i>Blood</i> , 2011, 117, 6172-6183.	0.6	132
77	The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. <i>Oncogene</i> , 2011, 30, 4339-4349.	2.6	95
78	Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. <i>Cancer Cell</i> , 2011, 19, 664-678.	7.7	397
79	Coordinated Regulation of Polycomb Group Complexes through microRNAs in Cancer. <i>Cancer Cell</i> , 2011, 20, 187-199.	7.7	191
80	TMPRSS2-ERG-Mediated Feed-Forward Regulation of Wild-Type ERG in Human Prostate Cancers. <i>Cancer Research</i> , 2011, 71, 5387-5392.	0.4	42
81	Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. <i>Cancer Discovery</i> , 2011, 1, 35-43.	7.7	91
82	Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells. <i>Blood</i> , 2011, 118, 820-820.	0.6	0
83	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. <i>Eur Urol</i> 2010;58:12-8. <i>European Urology</i> , 2010, 58, e29-e30.	0.9	17
84	An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. <i>Cancer Cell</i> , 2010, 17, 443-454.	7.7	743
85	The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. <i>Oncogene</i> , 2010, 29, 5370-5380.	2.6	75
86	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , 2010, 16, 793-798.	15.2	436
87	Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer. <i>Neoplasia</i> , 2010, 12, 590-IN21.	2.3	305
88	Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer. <i>Science</i> , 2009, 326, 1230-1230.	6.0	334
89	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 10284-10289.	3.3	140
90	Tomlins et al. reply. <i>Nature</i> , 2009, 457, E2-E3.	13.7	6

#	ARTICLE	IF	CITATIONS
91	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. <i>Nature</i> , 2009, 457, 910-914.	13.7	1,944
92	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. <i>Nature Biotechnology</i> , 2009, 27, 1005-1011.	9.4	69
93	RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease. <i>Neoplasia</i> , 2009, 11, 956-963.	2.3	76
94	Proteomic Interrogation of Androgen Action in Prostate Cancer Cells Reveals Roles of Aminoacyl tRNA Synthetases. <i>PLoS ONE</i> , 2009, 4, e7075.	1.1	54
95	Repression of E-cadherin by the polycomb group protein EZH2 in cancer. <i>Oncogene</i> , 2008, 27, 7274-7284.	2.6	526
96	The Role of SPINK1 in ETS Rearrangement-Negative Prostate Cancers. <i>Cancer Cell</i> , 2008, 13, 519-528.	7.7	303
97	Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1. <i>American Journal of Pathology</i> , 2008, 172, 893-904.	1.9	60
98	Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer. <i>Neoplasia</i> , 2008, 10, 177-IN9.	2.3	608
99	Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer. <i>Neoplasia</i> , 2008, 10, 1285-IN35.	2.3	89
100	Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer. <i>Science</i> , 2008, 322, 1695-1699.	6.0	995
101	A Fluorescence <i>In situ</i> Hybridization Screen for E26 Transformation-Specific Aberrations: Identification of DDX5-ETV4 Fusion Protein in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 7629-7637.	0.4	139
102	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer. <i>Cancer Research</i> , 2008, 68, 73-80.	0.4	244
103	A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. <i>Cancer Research</i> , 2007, 67, 10657-10663.	0.4	308
104	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19488-19493.	3.3	171
105	Effect of Epidermal Growth Factor Receptor Inhibitor Class in the Treatment of Head and Neck Cancer with Concurrent Radiochemotherapy <i>In vivo</i> . <i>Clinical Cancer Research</i> , 2007, 13, 2512-2518.	3.2	48
106	Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma. <i>Cancer Research</i> , 2007, 67, 3461-3467.	0.4	86
107	Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. <i>Neoplasia</i> , 2007, 9, 166-180.	2.3	1,847
108	Molecular Concepts Analysis Links Tumors, Pathways, Mechanisms, and Drugs. <i>Neoplasia</i> , 2007, 9, 443-IN9.	2.3	124

#	ARTICLE	IF	CITATIONS
109	Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. <i>Oncogene</i> , 2007, 26, 3431-3439.	2.6	66
110	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , 2007, 448, 595-599.	13.7	743
111	Integrative Genomics Analysis Reveals Silencing of β^2 -Adrenergic Signaling by Polycomb in Prostate Cancer. <i>Cancer Cell</i> , 2007, 12, 419-431.	7.7	204
112	Defining Aggressive Prostate Cancer Using a 12-Gene Model. <i>Neoplasia</i> , 2006, 8, 59-68.	2.3	90
113	ADAM15 Disintegrin Is Associated with Aggressive Prostate and Breast Cancer Disease. <i>Neoplasia</i> , 2006, 8, 319-329.	2.3	85
114	Differential proteomic alterations between localised and metastatic prostate cancer. <i>British Journal of Cancer</i> , 2006, 95, 425-430.	2.9	27
115	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. <i>International Journal of Cancer</i> , 2006, 118, 1041-1050.	2.3	41
116	Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2â€™,5â€™-oligoadenylate synthetase from prostate cancer cells. <i>Nucleic Acids Research</i> , 2006, 34, 6684-6695.	6.5	48
117	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. <i>Journal of Experimental Medicine</i> , 2006, 203, 203-213.	4.2	199
118	A Systems Approach to Model Metastatic Progression: Figure 1.. <i>Cancer Research</i> , 2006, 66, 5537-5539.	0.4	9
119	Ataxia Telangiectasia Mutated Down-regulates Phospho-Extracellular Signal-Regulated Kinase 1/2 via Activation of MKP-1 in Response to Radiation. <i>Cancer Research</i> , 2006, 66, 11554-11559.	0.4	25
120	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. <i>Journal of Cell Biology</i> , 2006, 172, iX-iX.	2.3	0
121	Recurrent Fusion of TMRSS2 and ETS Transcription Factor Genes in Prostate Cancer. <i>Science</i> , 2005, 310, 644-648.	6.0	3,541
122	Probabilistic model of the human protein-protein interaction network. <i>Nature Biotechnology</i> , 2005, 23, 951-959.	9.4	380
123	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , 2005, 8, 393-406.	7.7	731
124	Â-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1418-1423.	1.1	51
125	Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. <i>Cancer Research</i> , 2005, 65, 11259-11264.	0.4	272
126	The Unfolded Protein Response Modulates Toxicity of the Expanded Glutamine Androgen Receptor*. <i>Journal of Biological Chemistry</i> , 2005, 280, 21264-21271.	1.6	53

#	ARTICLE	IF	CITATIONS
127	Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). <i>Cancer Research</i> , 2005, 65, 3328-3335.	0.4	359
128	The Polycomb Group Protein EZH2 Impairs DNA Repair in Breast Epithelial Cells. <i>Neoplasia</i> , 2005, 7, 1011-1019.	2.3	86
129	Autoantibody Signatures in Prostate Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 1224-1235.	13.9	581
130	The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression. <i>Cancer Research</i> , 2004, 64, 825-829.	0.4	126
131	Natural antibodies sustain differentiation and maturation of human dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14210-14215.	3.3	100
132	Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. <i>International Immunology</i> , 2004, 16, 517-524.	1.8	33
133	Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer. <i>Cancer Research</i> , 2004, 64, 3814-3822.	0.4	145
134	JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence. <i>Cancer Research</i> , 2004, 64, 6854-6857.	0.4	310
135	Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases. <i>Cancer Research</i> , 2004, 64, 9209-9216.	0.4	816
136	C5a-Induced Gene Expression in Human Umbilical Vein Endothelial Cells. <i>American Journal of Pathology</i> , 2004, 164, 849-859.	1.9	152
137	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 11606-11611.	3.3	1,482
138	Molecular Cross-talk between the TRAIL and Interferon Signaling Pathways. <i>Journal of Biological Chemistry</i> , 2002, 277, 575-585.	1.6	89
139	Î±-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1662.	3.8	565
140	Î±-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation. <i>American Journal of Pathology</i> , 2002, 161, 841-848.	1.9	121
141	Changes in Differential Gene Expression because of Warm Ischemia Time of Radical Prostatectomy Specimens. <i>American Journal of Pathology</i> , 2002, 161, 1743-1748.	1.9	138
142	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , 2002, 419, 624-629.	13.7	2,411
143	Delineation of prognostic biomarkers in prostate cancer. <i>Nature</i> , 2001, 412, 822-826.	13.7	1,551